血栓通与阿司匹林对ITGB3基因多态性药物抵抗患者治疗作用的研究

摘要

目的 探讨中药制剂血栓通及阿司匹林抗血小板治疗脑卒中以及 ITGB3基因多态性对治疗效果的相关性.方法 收集了192例脑梗死患者,随机分为4组(阿司匹林组、血栓通组、血栓通+阿司匹林组、阿司匹林+氯吡格雷组)进行治疗,通过一般资料及测定生化指标和血栓弹力图,同时提取静脉血全基因组DNA,采用Snapshot方法检测ITGB3基因型,分析4组患者的血小板抑制情况,比较各组结果.结果 整体水平上,各组经药物治疗后,血小板抑制率显著提高,血栓通治疗对3种ITGB3基因型 AA、AG、GG患者血小板抑制率显著高于阿司匹林组,且组间没有显著性差异.结论 中药制剂血栓通可以抑制血小板聚集发挥药效,并且突变型 ITGB3基因 AA及 GG不会对血栓通产生抵抗.%OBJECTIVE To investigate the relationship between ITGB3 gene polymorphism and therapeutic effects of XueShuanTong and aspirin on cerebral infarction with anti-platelet.METHODS 192 patients with cerebral infarction were collected and randomly divided into 4 groups.According to patients general information,biomedical index and thromboelastogram,DNA genome were extracted from ve-nous blood and detected by using Snapshot method,and then analyzed the situations of anti-platelet and compared the results of 4 groups.RESULTS Generally,the inhibitory ratio of platelet increased obviously after the patients were treated with drugs.Compared with aspirin group,the inhibitory ratio of platelet increased obviously in patients with ITGB3 genes(AA,AG,GG)treated by XueShuanTong pharma-ceutics,and no significant difference appeared among these 3 groups.CONCLUSION XueShuanTong pharmaceutics can inhibit platelet aggregation,which will prevent the drug resistance in patients with mutant ITGB3 genes(AA and GG).